<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153659</url>
  </required_header>
  <id_info>
    <org_study_id>E3810-A001-038</org_study_id>
    <nct_id>NCT01153659</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets</brief_title>
  <official_title>A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets to H. Pylori-Negative Healthy Subjects in a 5-day Treatment Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      This will be a randomized, open-label, single-center, 3-way crossover study in healthy
      subjects who are confirmed to be Helicobacter pylori (H. pylori)-negative. The study will
      consist of 3 study periods separated by a washout period of at least 7 days. Subjects will
      receive study drugs once daily for 5 days. Barring any safety concerns, subjects will be
      discharged from the study on Day 6 of Period 3 after completion of discharge procedures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time that intragastric pH remains &gt;4</measure>
    <time_frame>24-hr period post-dose on Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of day- and night-time periods with intragastric pH &gt;4</measure>
    <time_frame>Days 1 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and duration of nocturnal acid breakthrough (NAB) episodes</measure>
    <time_frame>Days 1 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with nocturnal acid breakthrough (NAB) episodes</measure>
    <time_frame>Days 1 and 5</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E3810</intervention_name>
    <description>RAB ER 50 mg capsule once per day on Days 1-5</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aciphex (rabeprazole)</intervention_name>
    <description>Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium (esomeprazole)</intervention_name>
    <description>Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion:

          -  Healthy male and female subjects, including women of child-bearing potential, aged 18
             to 55 years, inclusive

          -  Subjects who are able to tolerate the insertion and placement of a pH probe on 2
             occasions per study period (Day -1 and Day 5)

        Key Exclusion:

          -  Subjects who are H. pylori-positive

          -  Subjects who have a history of any gastrointestinal disorder or surgery likely to
             influence drug absorption (e.g., history of gastric resection)

          -  Known hypersensitivity to rabeprazole, esomeprazole, or related compounds or any
             ingredient in the formulations

          -  Other standard clinical pharmacology exclusion criteria for healthy volunteers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Miner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Foundation for Digestive Research, 1000 N. Lincoln, Suite 210, Oklahoma City, OK 73104 USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma Foundation for Digestive Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rabeprazole</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>h. pylori-negative</keyword>
  <keyword>nocturnal acid breakthrough</keyword>
  <keyword>intragastric pH, PK/PD</keyword>
  <keyword>effect on gastric pH in healthy, H. pylori-Negative subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

